XOMA (NASDAQ:XOMA) Raised to “Hold” at StockNews.com

XOMA (NASDAQ:XOMA) was upgraded by stock analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued to investors on Friday.

Separately, HC Wainwright restated a “buy” rating and set a $104.00 price target on shares of XOMA in a report on Friday, March 28th.

XOMA Stock Up 1.4 %

XOMA opened at $19.97 on Friday. The stock’s fifty day simple moving average is $22.14 and its 200 day simple moving average is $26.20. The company has a current ratio of 7.52, a quick ratio of 7.52 and a debt-to-equity ratio of 1.28. XOMA has a 1-year low of $18.35 and a 1-year high of $35.00. The stock has a market cap of $238.70 million, a PE ratio of -5.74 and a beta of 1.00.

XOMA (NASDAQ:XOMA) last released its earnings results on Monday, March 17th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.17). XOMA had a negative net margin of 151.34% and a negative return on equity of 24.95%. The firm had revenue of $8.70 million during the quarter, compared to analyst estimates of $8.75 million. As a group, research analysts expect that XOMA will post -1.41 earnings per share for the current year.

Insider Transactions at XOMA

In other XOMA news, CIO Bradley Sitko bought 2,000 shares of the firm’s stock in a transaction dated Monday, April 7th. The stock was purchased at an average cost of $24.70 per share, with a total value of $49,400.00. Following the transaction, the executive now directly owns 5,045 shares in the company, valued at $124,611.50. This trade represents a 65.68 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the business’s stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $26.10, for a total transaction of $13,069,366.20. The disclosure for this sale can be found here. Insiders bought a total of 29,312 shares of company stock worth $735,061 in the last quarter. 7.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. GAMMA Investing LLC boosted its holdings in XOMA by 1,063.8% in the 1st quarter. GAMMA Investing LLC now owns 1,734 shares of the biotechnology company’s stock worth $35,000 after buying an additional 1,585 shares during the period. Woodline Partners LP lifted its position in shares of XOMA by 63.9% during the fourth quarter. Woodline Partners LP now owns 156,266 shares of the biotechnology company’s stock worth $4,107,000 after acquiring an additional 60,927 shares in the last quarter. Nuveen Asset Management LLC boosted its holdings in shares of XOMA by 3.8% in the fourth quarter. Nuveen Asset Management LLC now owns 14,363 shares of the biotechnology company’s stock worth $377,000 after acquiring an additional 527 shares during the period. Bank of America Corp DE grew its position in shares of XOMA by 34.7% in the fourth quarter. Bank of America Corp DE now owns 7,796 shares of the biotechnology company’s stock valued at $205,000 after purchasing an additional 2,009 shares in the last quarter. Finally, Northern Trust Corp raised its stake in shares of XOMA by 1.5% during the 4th quarter. Northern Trust Corp now owns 91,181 shares of the biotechnology company’s stock valued at $2,396,000 after purchasing an additional 1,340 shares during the period. Institutional investors own 95.92% of the company’s stock.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.